XML 115 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Tables)
12 Months Ended
Aug. 31, 2019
Statements [Line Items]  
Disclosure of detailed information about effective income tax expense recovery [Table Text Block]
  August 31,
2019
  August 31,
2018
  August 31,
2017
 
                   
Net loss for the year before income taxes $ 3,541,011   $ 3,458,976   $ 3,674,789  
Combined Canadian federal and provincial tax rate   25.0%     25.1%     25.0%  
                   
Expected income tax recovery at statutory rates   885,253     868,203     918,697  
Share based compensation   (19,711 )   (37,620 )   (45,777 )
Non-deductible financing transaction costs   (20,074 )   (89,678 )   (90,372 )
Other non-deductible expenses   (736 )   (2,864 )   (6,708 )
CEE incurred applied to flow-through shares   (179,086 )   (476,559 )   (563,796 )
Amortization of flow-through share premium   154,676     218,232     317,468  
Non-taxable (non-deductible) change in fair value warrants of financial instruments   (62,434 )   6,706     50,456  
Losses and other deductions for which no benefit has been recognized   (603,212 )   (268,188 )   (262,500 )
                   
Deferred income tax recoveries $ 154,676   $ 218,232   $ 317,468  
Disclosure of deferred taxes [Table Text Block]
    August 31,
2019
    August 31,
2018
 
Deferred income tax assets            
Exploration and evaluation assets $ 4,721,336   $ 4,647,258  
Scientific research and experimental developmental expenditures   5,424,332     5,527,640  
    10,145,668     10,174,898  
Deferred income tax liabilities            
Property plant and equipment   (10,145,668 )(1)   (10,174,898 )
             
Net deferred income tax assets $ -   $ -  

(1) Included the deferred income tax liability related to the carrying amount of Asset Held for Sale.

Disclosure of temporary difference, unused tax losses and unused tax credits [Table Text Block]
  August 31,
2019
  August 31,
2018
 
             
Non-capital loss carryforwards $ 35,630,141   $ 33,460,535  
Scientific research and experimental developmental expenditures   5,670,428     5,345,287  
Share issuance costs   458,359     781,253  
Capital loss carry forwards   2,294,535     2,294,535  
             
Deductible temporary differences not recognized $ 44,053,463   $ 41,881,610  
Disclosure of detailed information about non-capital losses [Table Text Block]
2026 $              156,000
2027 232,000
2028 847,000
2029 914,000
2030 1,584,000
2031 3,050,000
2032 3,601,000
2033 4,151,000
2034 4,211,000
2035 4,397,000
2036 3,008,000
2037 2,805,000
2038 2,837,000
2039 2,170,000
Disclosure of detailed information about operating losses [Table Text Block]
2031 $              5,000
2032 2,000
2033 3,000
2034 1,658,000